Figure S1. Representative images for IHC scoring of KIF2A with different intensity and density (magnification, x200). KIF2A, kinesin family member 2A; IHC, immunohistochemistry.

Staining intensity

O point (negative)

1 point (weak)

O point (0%)

1 point (1% to 25%)

2 points (26% to 50%)


2 points (moderate)


3 points (strong)


3 points (51% to 75%)

4 points (>75%)

Figure S2. KIF2A mRNA expression is not associated with DFS or OS of patients with PTC. Association of KIF2A mRNA expression with (A) DFS and (B) OS in patients with PTC. KIF2A, kinesin family member 2A; DFS, disease-free survival; OS, overall survival; PTC, papillary thyroid carcinoma; HR, hazard ratio.







	HR (95% CI)	OS rate	
		3-year	5-year
KIF2A low	Reference	100.0%	95.8%
KIF2A high	5.954 (0.715-49.553)	88.6%	78.4%

Figure S3. Subgroup analyses of prognosis in patients with PTC with different carcinoma and para-carcinoma KIF2A expression profiles. Association of (A) DFS and (B) OS in patients with PTC with different carcinoma and paracarcinoma KIF2A expression profiles. KIF2A, kinesin family member 2A; DFS, disease-free survival; OS, overall survival; PTC, papillary thyroid carcinoma.

